Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

Why Is Design Therapeutics Stock Moving Lower Today?

By Vandana Singh

August 15, 9:04 AM

Design Therapeutics Inc (NASDAQ: DSGN) reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical trial of DT-216 in

DSGN

News

AGBA Reported To NASDAQ And SEC In Relation To Irregular Trading Activities In AGBA Shares

By Benzinga Newsdesk

October 3, 9:09 AM

NASDAQ-listed, AGBA Group Holding Limited ("AGBA" or the "Company"), the leading one-stop financial supermarket in Hong Kong, provide updates on its actions against certain irregular trading activities in the Company's

AGBA

Earnings

Looking Into Great Lakes Dredge & Dock’s Return On Capital Employed

By Benzinga Insights

November 9, 10:54 AM

Benzinga Pro data, Great Lakes Dredge & Dock (NASDAQ:GLDD) reported Q3 sales of $158.35 million. Earnings fell to a loss of $9.91 million, resulting in a 145.72% decrease from last quarter.

GLDD

Morgan Stanley Appoints ‘Battle-Tested’ Edward Pick As CEO, James Gorman To Assume Role Of Executive Chairman

By Nabaparna Bhattacharya

October 26, 8:43 AM

Morgan Stanley (NYSE: MS) appointed its Co-President, Edward (Ted) Pick, as the

Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Related Posts

Why Is Design Therapeutics Stock Moving Lower Today?

AGBA Reported To NASDAQ And SEC In Relation To Irregular Trading Activities In AGBA Shares

Looking Into Great Lakes Dredge & Dock’s Return On Capital Employed

Morgan Stanley Appoints ‘Battle-Tested’ Edward Pick As CEO, James Gorman To Assume Role Of Executive Chairman